It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The majority of Alzheimer’s disease (AD) cases are late-onset and occur sporadically, however most mouse models of the disease harbor pathogenic mutations, rendering them better representations of familial autosomal-dominant forms of the disease. Here, we generated knock-in mice that express wildtype human Aβ under control of the mouse App locus. Remarkably, changing 3 amino acids in the mouse Aβ sequence to its wild-type human counterpart leads to age-dependent impairments in cognition and synaptic plasticity, brain volumetric changes, inflammatory alterations, the appearance of Periodic Acid-Schiff (PAS) granules and changes in gene expression. In addition, when exon 14 encoding the Aβ sequence was flanked by loxP sites we show that Cre-mediated excision of exon 14 ablates hAβ expression, rescues cognition and reduces the formation of PAS granules.
Most instances of Alzheimer’s disease (AD) are sporadic or not associated with a particular mutation. Here, the authors develop knock-in mice that express wildtype human Aβ under control of the mouse App locus, which may have potential for modelling some aspects of sporadic late onset AD.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details














1 University of California, Institute for Memory Impairments and Neurological Disorders, Irvine, USA (GRID:grid.266093.8) (ISNI:0000 0001 0668 7243); University of California, Department of Neurobiology and Behavior, Irvine, USA (GRID:grid.266093.8) (ISNI:0000 0001 0668 7243); Networking Research Center on Neurodegenerative Diseases (CIBERNED), University of Malaga, Department of Cell Biology, Genetic and Physiology, Faculty of Sciences, Instituto de Investigacion Biomedica de Malaga-IBIMA, Malaga, Spain (GRID:grid.10215.37) (ISNI:0000 0001 2298 7828)
2 University of California, Institute for Memory Impairments and Neurological Disorders, Irvine, USA (GRID:grid.266093.8) (ISNI:0000 0001 0668 7243)
3 University of California, Institute for Memory Impairments and Neurological Disorders, Irvine, USA (GRID:grid.266093.8) (ISNI:0000 0001 0668 7243); Networking Research Center on Neurodegenerative Diseases (CIBERNED), University of Malaga, Department of Cell Biology, Genetic and Physiology, Faculty of Sciences, Instituto de Investigacion Biomedica de Malaga-IBIMA, Malaga, Spain (GRID:grid.10215.37) (ISNI:0000 0001 2298 7828)
4 University of California, Institute for Memory Impairments and Neurological Disorders, Irvine, USA (GRID:grid.266093.8) (ISNI:0000 0001 0668 7243); University of California, Department of Neurobiology and Behavior, Irvine, USA (GRID:grid.266093.8) (ISNI:0000 0001 0668 7243)
5 University of California, Department of Developmental and Cell Biology, Irvine, USA (GRID:grid.266093.8) (ISNI:0000 0001 0668 7243)
6 Networking Research Center on Neurodegenerative Diseases (CIBERNED), University of Malaga, Department of Cell Biology, Genetic and Physiology, Faculty of Sciences, Instituto de Investigacion Biomedica de Malaga-IBIMA, Malaga, Spain (GRID:grid.10215.37) (ISNI:0000 0001 2298 7828)
7 University of California, Institute for Memory Impairments and Neurological Disorders, Irvine, USA (GRID:grid.266093.8) (ISNI:0000 0001 0668 7243); University of California, Division of Occupational and Environmental Medicine, Department of Medicine. Center for Occupational and Environmental Health (COEH), Irvine, USA (GRID:grid.266093.8) (ISNI:0000 0001 0668 7243)
8 University of Texas Health Science Center at Houston, The Mitchell Center for Alzheimer’s Disease and Related Brain Disorders, Department of Neurology, McGovern Medical School, Houston, USA (GRID:grid.267308.8) (ISNI:0000 0000 9206 2401)
9 Networking Research Center on Neurodegenerative Diseases (CIBERNED), University of Malaga, Department of Cell Biology, Genetic and Physiology, Faculty of Sciences, Instituto de Investigacion Biomedica de Malaga-IBIMA, Malaga, Spain (GRID:grid.10215.37) (ISNI:0000 0001 2298 7828); University of Texas Health Science Center at Houston, The Mitchell Center for Alzheimer’s Disease and Related Brain Disorders, Department of Neurology, McGovern Medical School, Houston, USA (GRID:grid.267308.8) (ISNI:0000 0000 9206 2401)
10 University of California, Institute for Memory Impairments and Neurological Disorders, Irvine, USA (GRID:grid.266093.8) (ISNI:0000 0001 0668 7243); University of California, Department of Neurobiology and Behavior, Irvine, USA (GRID:grid.266093.8) (ISNI:0000 0001 0668 7243); University of California, Department of Molecular Biology and Biochemistry, Irvine, USA (GRID:grid.266093.8) (ISNI:0000 0001 0668 7243)